Larry Johnson, MD
Pulmonary Disease · Little Rock, ARNPI 1184714669
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $182 of the $216 with a category attached, or 84.4%. Vertex accounts for 84.4% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $140, 2.3 times the $60 reported in 2019. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 4 payments — averaging $53.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$182
- Bayer$18
- AstraZeneca$15
Across 26 payments — averaging $32,574 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$791K
- AbbVie$32K
- Boehringer Ingelheim$21K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Food & beverage$18284%
- Education$3416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 2 | $182 |
| Bayer | 1 | $18 |
| AstraZeneca | 1 | $15 |
How this compares
$216 in reported general payments places this provider in the 10th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 126 | $3,224,325 |
| ZenpepLipase/Protease/Amylase | 104 | $487,007 |
| SymdekoTezacaftor/Ivacaftor | 11 | $255,917 |
| CreonLipase/Protease/Amylase | 37 | $181,377 |
| CaystonAztreonam Lysine | 14 | $158,301 |
| OpsumitMacitentan | 12 | $151,857 |
| Ambrisentan | 21 | $102,960 |
| Tadalafil | 36 | $33,363 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $10,969 |
| Ventolin HfaAlbuterol Sulfate | 68 | $4,191 |
| Ursodiol | 53 | $2,994 |
| Sildenafil Citrate | 12 | $2,664 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,360 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,161 |
| Azithromycin | 50 | $620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta, Symdeko | $182 | $3,480,242137 claims |
| AstraZenecaSymbicort | $15 | $10,96927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Little Rock
- Nikhil MeenaLittle Rock$63K
- Hanan Khadam-MakhoulLittle Rock$15K
- Raghu ReddyLittle Rock$13K
- Eyad AbochaleLittle Rock$11K
- Krishna Siva Sai KakkeraLittle Rock$11K
- Samer HomsiLittle Rock$9K
- Nathan HillLittle Rock$9K
- Jose CaceresLittle Rock$6K
- Moeezullah BegLittle Rock$5K
- Rosa ArancibiaLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.